Enliven Therapeutics Inc (ELVN)

$21.65 -1.35 (-5.87%)
Market Cap 1.13B
Revenue (ttm) 0.00
Net Income (ttm) -89.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 900,900
Avg Vol 548,410
Day's Range N/A - N/A
Shares Out 49.07M
Stochastic %K 56%
Beta 0.83
Analysts Strong Sell
Price Target $41.00

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
IN0V8
IN0V8 Jul. 2 at 1:53 PM
$ELVN Watch / Opportunity H.C. Wainwright raises target price to $48 from $40
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 2 at 11:03 AM
WATCHLIST JUL 02 2025 $GRYP American Bitcoin Expected To Trade On Nasdaq Under Ticker Symbol "ABTC" Following Stock-For-Stock Merger With Gryphon Digital Mining $TTD Citigroup Maintains Buy on Trade Desk, Raises Price Target to $90 $HUT Hut 8's Four Natural Gas-Fired Power Plants In Ontario Bags 5-Yr Capacity Contract With Ontario Independent Electricity System Operator $VIAV VIAVI Adds Colocation to Arizona Open RAN Lab, Boosting Secure Testing for US Telecom Innovation $ELVN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
0 · Reply
JarvisFlow
JarvisFlow Jul. 2 at 11:00 AM
HC Wainwright & Co. has updated their rating for Enliven Therapeutics ( $ELVN ) to Buy with a price target of 48.
0 · Reply
TopLight2025
TopLight2025 Jun. 23 at 3:28 PM
$ELVN
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 4:50 AM
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ $ELVN https://stocktwits.com/news/equity/markets/enliven-short-interest-falls-to-14-month-low-after-leukemia-trial-data-goldman-initiates-with-buy/chmPAwdRR59
1 · Reply
Quantumup
Quantumup Jun. 20 at 7:40 PM
Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:
1 · Reply
TopLight2025
TopLight2025 Jun. 20 at 6:11 PM
$ELVN
0 · Reply
Quantumup
Quantumup Jun. 20 at 5:50 PM
TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."
0 · Reply
TopLight2025
TopLight2025 Jun. 16 at 9:49 PM
$ELVN https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nPn7yLpzPa&default-theme=true
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 1:38 PM
Goldman Sachs updates rating for Enliven Therapeutics ( $ELVN ) to Buy, target set at 37.
0 · Reply
Latest News on ELVN
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 16, 2025, 4:05 PM EDT - 4 weeks ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 9:30 AM EDT - 4 weeks ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 4 weeks ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 13, 2025, 6:02 AM EDT - 4 weeks ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025, 4:05 PM EDT - 7 weeks ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 14, 2025, 4:05 PM EDT - 2 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

May 14, 2025, 9:56 AM EDT - 2 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Apr 2, 2025, 4:03 PM EDT - 3 months ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 4 months ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 4:05 PM EDT - 4 months ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:05 PM EST - 5 months ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 5 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Enliven's Early Data Stands Out From Peers

Jan 7, 2025, 12:28 AM EST - 6 months ago

Enliven's Early Data Stands Out From Peers

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 13, 2024, 4:05 PM EST - 8 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 8 months ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 9 months ago

Why Enliven is this analyst's top biotech stock pick

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 28, 2024, 9:35 AM EDT - 10 months ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Sep 18, 2024, 4:05 PM EDT - 10 months ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 29, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 11, 2024, 7:55 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Aug 18, 2023, 12:57 PM EDT - 2 years ago

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 23, 2023, 5:20 PM EST - 2 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 2 years ago

Imara Announces Stockholder Approval of Merger With Enliven

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Jan 25, 2023, 1:07 PM EST - 2 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 2 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Imara: Potential Liquidation

Sep 29, 2022, 3:06 PM EDT - 3 years ago

Imara: Potential Liquidation

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 3 years ago

Read Why Imara Shares Are Falling Today

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Apr 5, 2022, 6:45 AM EDT - 3 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Mar 15, 2022, 11:06 AM EDT - 3 years ago

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 7:00 AM EST - 3 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 7:00 AM EST - 3 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 3 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 25, 2022, 7:00 AM EST - 3 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Jan 5, 2022, 7:00 AM EST - 3 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 14, 2021, 7:00 AM EST - 3 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Nov 22, 2021, 10:36 AM EST - 3 years ago

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 22, 2021, 7:00 AM EST - 3 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Nov 16, 2021, 11:34 AM EST - 3 years ago

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Nov 16, 2021, 7:00 AM EST - 3 years ago

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript

Nov 9, 2021, 4:48 PM EST - 4 years ago

IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Nov 9, 2021, 7:00 AM EST - 4 years ago

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Nov 4, 2021, 4:01 PM EDT - 4 years ago

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

IN0V8
IN0V8 Jul. 2 at 1:53 PM
$ELVN Watch / Opportunity H.C. Wainwright raises target price to $48 from $40
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 2 at 11:03 AM
WATCHLIST JUL 02 2025 $GRYP American Bitcoin Expected To Trade On Nasdaq Under Ticker Symbol "ABTC" Following Stock-For-Stock Merger With Gryphon Digital Mining $TTD Citigroup Maintains Buy on Trade Desk, Raises Price Target to $90 $HUT Hut 8's Four Natural Gas-Fired Power Plants In Ontario Bags 5-Yr Capacity Contract With Ontario Independent Electricity System Operator $VIAV VIAVI Adds Colocation to Arizona Open RAN Lab, Boosting Secure Testing for US Telecom Innovation $ELVN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
0 · Reply
JarvisFlow
JarvisFlow Jul. 2 at 11:00 AM
HC Wainwright & Co. has updated their rating for Enliven Therapeutics ( $ELVN ) to Buy with a price target of 48.
0 · Reply
TopLight2025
TopLight2025 Jun. 23 at 3:28 PM
$ELVN
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 4:50 AM
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ $ELVN https://stocktwits.com/news/equity/markets/enliven-short-interest-falls-to-14-month-low-after-leukemia-trial-data-goldman-initiates-with-buy/chmPAwdRR59
1 · Reply
Quantumup
Quantumup Jun. 20 at 7:40 PM
Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:
1 · Reply
TopLight2025
TopLight2025 Jun. 20 at 6:11 PM
$ELVN
0 · Reply
Quantumup
Quantumup Jun. 20 at 5:50 PM
TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."
0 · Reply
TopLight2025
TopLight2025 Jun. 16 at 9:49 PM
$ELVN https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nPn7yLpzPa&default-theme=true
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 1:38 PM
Goldman Sachs updates rating for Enliven Therapeutics ( $ELVN ) to Buy, target set at 37.
0 · Reply
RunnerSignals
RunnerSignals Jun. 13 at 8:31 PM
Big Movers Making Noise! $TORO $SSL $CNTB $ELVN $SEDG Eyes on Monday's action! https://stocksrunner.com/news/2025-06-13-top-stock-market-movers-surge-on-big-news
0 · Reply
RunnerSignals
RunnerSignals Jun. 13 at 8:25 PM
comeback kings $GNLX soared $ELVN came alive $EU fueled up $GEVO sparked interest and $CLNE cleaned up with a tidy close
0 · Reply
TopLight2025
TopLight2025 Jun. 13 at 4:33 PM
$ELVN
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 13 at 12:25 PM
$ELVN Going higher. pt 22
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 13 at 12:10 PM
$ELVN (-1.6% pre) Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ooc.bz/l/67967
0 · Reply
DonCorleone77
DonCorleone77 Jun. 13 at 10:20 AM
$ELVN Enliven announces $200M offering of common stock, warrants Enliven Therapeutics announced that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. Jefferies, Goldman Sachs & Co., TD Cowen and Mizuho are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.
0 · Reply
swingingtech
swingingtech Jun. 4 at 9:32 PM
$ELVN https://wallstreetwaves.com/enliven-therapeutics-elvn-stock-surpasses-200-day-moving-average/
0 · Reply
justiceforb_85
justiceforb_85 May. 16 at 2:10 AM
$ELVN do think it's wise to focus on ELVN-001 and put ELVN-002 on the back burner for now.
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Enliven Therapeutics ( $ELVN ), setting the rating to Buy with a target price of 39 → 40.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 14 at 1:58 PM
$ELVN's Phase 1 data for ELVN-001 in resistant CML continues to impress: 44% MMR rate at 24 weeks, 74 patients with median 26-week treatment duration, and a clean safety profile. Upcoming EHA presentation (June 13) could cement its best-in-class potential. Pivotal trial plans in 2026 remain the key catalyst. https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-001-in-cml-and-oral-presentation-at-the-eha-2025-congress-302455412.html
0 · Reply
Armonica423
Armonica423 May. 6 at 5:52 PM
$ELVN CYDY
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 11:37 PM
$ELVN Digging ELVN's precision oncology approach. BCR-ABL and HER2 programs looking promising. Phase 1 data showing potential. Watching closely for 2025 updates. Could be an interesting play in targeted cancer therapeutics. strong article: https://beyondspx.com/article/enliven-therapeutics-elvn-a-promising-precision-oncology-player-emerging-from-the-shadows
0 · Reply